User login
Commentary: Alternate considerations in treating IBS, November 2022
The study by Bureychak and colleagues highlights the differences between men and women with irritable bowel syndrome (IBS) as it relates to living arrangements, educational level, and employment status. Men with IBS had similarly reported educational levels, living arrangements, and household economy satisfaction as their peers without IBS. In stark contrast, women with IBS were more likely to live alone and achieve a lower educational level than were their peers without IBS. This study calls into question how much do we know about gender implications in IBS? Gender and sex may have a role in the biopsychosocial model of IBS.
Acupuncture is a very popular treatment strategy in some areas of the world and is extensively applied in Chinese practice. Though this is a regularly applied treatment, a direct comparison with first-line antispasmodics has not been previously completed. The study by Shi and colleagues sought to compare the treatment of IBS using an adjusted indirect treatment comparison meta-analysis. This study proves that cimetropium was the most effective for relieving abdominal pain, whereas drotaverine, acupuncture, and pinaverium remained superior to the placebo. That being said, acupuncture was shown to be superior in relieving global IBS symptoms and caused fewer side effects than did antispasmodics. This shows that acupuncture may have a role in the treatment algorithm for IBS even outside of China, where it is used broadly.
The study by Formica and colleagues provides new insights on the etiology and pathogenesis of IBS. These insights include the positive correlation between disgust sensitivity and IBS quality of life (QOL) scores. The relationship between IBS and the emotional intensity of the experience of disgust is discussed throughout this study and more severe IBS-QOL scores were linked to those with high levels of disgust sensitivity. This study had gender limitations because of the low number of male participants, so these correlations were patterned mostly in female participants.
The study by Bureychak and colleagues highlights the differences between men and women with irritable bowel syndrome (IBS) as it relates to living arrangements, educational level, and employment status. Men with IBS had similarly reported educational levels, living arrangements, and household economy satisfaction as their peers without IBS. In stark contrast, women with IBS were more likely to live alone and achieve a lower educational level than were their peers without IBS. This study calls into question how much do we know about gender implications in IBS? Gender and sex may have a role in the biopsychosocial model of IBS.
Acupuncture is a very popular treatment strategy in some areas of the world and is extensively applied in Chinese practice. Though this is a regularly applied treatment, a direct comparison with first-line antispasmodics has not been previously completed. The study by Shi and colleagues sought to compare the treatment of IBS using an adjusted indirect treatment comparison meta-analysis. This study proves that cimetropium was the most effective for relieving abdominal pain, whereas drotaverine, acupuncture, and pinaverium remained superior to the placebo. That being said, acupuncture was shown to be superior in relieving global IBS symptoms and caused fewer side effects than did antispasmodics. This shows that acupuncture may have a role in the treatment algorithm for IBS even outside of China, where it is used broadly.
The study by Formica and colleagues provides new insights on the etiology and pathogenesis of IBS. These insights include the positive correlation between disgust sensitivity and IBS quality of life (QOL) scores. The relationship between IBS and the emotional intensity of the experience of disgust is discussed throughout this study and more severe IBS-QOL scores were linked to those with high levels of disgust sensitivity. This study had gender limitations because of the low number of male participants, so these correlations were patterned mostly in female participants.
The study by Bureychak and colleagues highlights the differences between men and women with irritable bowel syndrome (IBS) as it relates to living arrangements, educational level, and employment status. Men with IBS had similarly reported educational levels, living arrangements, and household economy satisfaction as their peers without IBS. In stark contrast, women with IBS were more likely to live alone and achieve a lower educational level than were their peers without IBS. This study calls into question how much do we know about gender implications in IBS? Gender and sex may have a role in the biopsychosocial model of IBS.
Acupuncture is a very popular treatment strategy in some areas of the world and is extensively applied in Chinese practice. Though this is a regularly applied treatment, a direct comparison with first-line antispasmodics has not been previously completed. The study by Shi and colleagues sought to compare the treatment of IBS using an adjusted indirect treatment comparison meta-analysis. This study proves that cimetropium was the most effective for relieving abdominal pain, whereas drotaverine, acupuncture, and pinaverium remained superior to the placebo. That being said, acupuncture was shown to be superior in relieving global IBS symptoms and caused fewer side effects than did antispasmodics. This shows that acupuncture may have a role in the treatment algorithm for IBS even outside of China, where it is used broadly.
The study by Formica and colleagues provides new insights on the etiology and pathogenesis of IBS. These insights include the positive correlation between disgust sensitivity and IBS quality of life (QOL) scores. The relationship between IBS and the emotional intensity of the experience of disgust is discussed throughout this study and more severe IBS-QOL scores were linked to those with high levels of disgust sensitivity. This study had gender limitations because of the low number of male participants, so these correlations were patterned mostly in female participants.
Commentary: IBS and comorbid conditions, October 2022
Three studies this month highlight the increased incidence of irritable bowel syndrome (IBS) in the setting of other chronic diseases, specifically diseases with an effect on the abdomen and pelvis:
- Fairbrass et al: Natural history and impact of IBS-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up
- Nabi et al: Endometriosis and IBS — a systematic review and meta-analyses
- Wang et al: Factors related to IBS and differences among subtypes — a cross-sectional study in the UK Biobank
Combined diseases can make assessment and treatment very difficult for clinicians. Having a thorough understanding of the pathophysiology and phenotype of each of these diseases is imperative to ensuring that they are managed to the standard of care. When these diseases are in remission and abdominal symptoms persist, it begs the question what is the cause? IBS should always be in the differential diagnosis. The dynamic relationship between the varying presentations of IBS and co-occurring conditions can greatly affect the patient's quality of life and experience with the healthcare system. Thus, it is vital to implement an interdisciplinary approach in order to comprehensively care for the patient and build a therapeutic relationship with the patient. Establishing short-term and long-term goals through shared decision-making will create a foundation of trust and allow for improved patient experience.
Three studies this month highlight the increased incidence of irritable bowel syndrome (IBS) in the setting of other chronic diseases, specifically diseases with an effect on the abdomen and pelvis:
- Fairbrass et al: Natural history and impact of IBS-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up
- Nabi et al: Endometriosis and IBS — a systematic review and meta-analyses
- Wang et al: Factors related to IBS and differences among subtypes — a cross-sectional study in the UK Biobank
Combined diseases can make assessment and treatment very difficult for clinicians. Having a thorough understanding of the pathophysiology and phenotype of each of these diseases is imperative to ensuring that they are managed to the standard of care. When these diseases are in remission and abdominal symptoms persist, it begs the question what is the cause? IBS should always be in the differential diagnosis. The dynamic relationship between the varying presentations of IBS and co-occurring conditions can greatly affect the patient's quality of life and experience with the healthcare system. Thus, it is vital to implement an interdisciplinary approach in order to comprehensively care for the patient and build a therapeutic relationship with the patient. Establishing short-term and long-term goals through shared decision-making will create a foundation of trust and allow for improved patient experience.
Three studies this month highlight the increased incidence of irritable bowel syndrome (IBS) in the setting of other chronic diseases, specifically diseases with an effect on the abdomen and pelvis:
- Fairbrass et al: Natural history and impact of IBS-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up
- Nabi et al: Endometriosis and IBS — a systematic review and meta-analyses
- Wang et al: Factors related to IBS and differences among subtypes — a cross-sectional study in the UK Biobank
Combined diseases can make assessment and treatment very difficult for clinicians. Having a thorough understanding of the pathophysiology and phenotype of each of these diseases is imperative to ensuring that they are managed to the standard of care. When these diseases are in remission and abdominal symptoms persist, it begs the question what is the cause? IBS should always be in the differential diagnosis. The dynamic relationship between the varying presentations of IBS and co-occurring conditions can greatly affect the patient's quality of life and experience with the healthcare system. Thus, it is vital to implement an interdisciplinary approach in order to comprehensively care for the patient and build a therapeutic relationship with the patient. Establishing short-term and long-term goals through shared decision-making will create a foundation of trust and allow for improved patient experience.
Commentary: Psychiatric Comorbidity, the Microbiome, and IBS, September 2022
In a study by Creed and colleagues, the presence of psychiatric disorders was the strongest predictor of subsequent irritable bowel syndrome (IBS) diagnosis. This highlights the importance of the brain-gut connection. It also enforces the need for obtaining a comprehensive history during the patient interview and adequate understanding of the patient's psychosocial status. Despite this study being somewhat limited, it does underscore the importance of psychiatric disorders as an important risk factor in the development of IBS.
Fecal and mucosal microbiota have been the focus of much research. A study by Hou and colleagues that showed distinct differences in the intestinal and fecal microbiomes of patients with constipation-predominant or diarrhea-predominant IBS, compared with healthy controls, highlights the importance of a balanced and diverse microbiome to maintain a healthy gut. The article notes specific genera of microbiota that were associated with intestinal pain. When microbiota diversity is limited, the incidence of IBS is increased. This reinforces the importance of promoting a healthy microbiome in all patients and appreciating the correlation of the microbiome with the development of IBS.
Internet-based cognitive-behavioral therapy may make it easier for patients to obtain therapy services. Kim and colleagues have shown this to be a cost-effective and efficacious way to deliver care. This care improves the quality of life for patients with IBS and is an effective intervention that is readily available. During pandemic times, the forum of online care also provides a safe way to deliver therapy services without the burden of the patient needing to commute to clinic and potentially be exposed to infectious disease. Given the relationship between IBS and psychiatric diagnoses noted by Creed and colleagues, it seems important to extend the availability of therapeutic interventions to as many patients with IBS as possible.
In a study by Creed and colleagues, the presence of psychiatric disorders was the strongest predictor of subsequent irritable bowel syndrome (IBS) diagnosis. This highlights the importance of the brain-gut connection. It also enforces the need for obtaining a comprehensive history during the patient interview and adequate understanding of the patient's psychosocial status. Despite this study being somewhat limited, it does underscore the importance of psychiatric disorders as an important risk factor in the development of IBS.
Fecal and mucosal microbiota have been the focus of much research. A study by Hou and colleagues that showed distinct differences in the intestinal and fecal microbiomes of patients with constipation-predominant or diarrhea-predominant IBS, compared with healthy controls, highlights the importance of a balanced and diverse microbiome to maintain a healthy gut. The article notes specific genera of microbiota that were associated with intestinal pain. When microbiota diversity is limited, the incidence of IBS is increased. This reinforces the importance of promoting a healthy microbiome in all patients and appreciating the correlation of the microbiome with the development of IBS.
Internet-based cognitive-behavioral therapy may make it easier for patients to obtain therapy services. Kim and colleagues have shown this to be a cost-effective and efficacious way to deliver care. This care improves the quality of life for patients with IBS and is an effective intervention that is readily available. During pandemic times, the forum of online care also provides a safe way to deliver therapy services without the burden of the patient needing to commute to clinic and potentially be exposed to infectious disease. Given the relationship between IBS and psychiatric diagnoses noted by Creed and colleagues, it seems important to extend the availability of therapeutic interventions to as many patients with IBS as possible.
In a study by Creed and colleagues, the presence of psychiatric disorders was the strongest predictor of subsequent irritable bowel syndrome (IBS) diagnosis. This highlights the importance of the brain-gut connection. It also enforces the need for obtaining a comprehensive history during the patient interview and adequate understanding of the patient's psychosocial status. Despite this study being somewhat limited, it does underscore the importance of psychiatric disorders as an important risk factor in the development of IBS.
Fecal and mucosal microbiota have been the focus of much research. A study by Hou and colleagues that showed distinct differences in the intestinal and fecal microbiomes of patients with constipation-predominant or diarrhea-predominant IBS, compared with healthy controls, highlights the importance of a balanced and diverse microbiome to maintain a healthy gut. The article notes specific genera of microbiota that were associated with intestinal pain. When microbiota diversity is limited, the incidence of IBS is increased. This reinforces the importance of promoting a healthy microbiome in all patients and appreciating the correlation of the microbiome with the development of IBS.
Internet-based cognitive-behavioral therapy may make it easier for patients to obtain therapy services. Kim and colleagues have shown this to be a cost-effective and efficacious way to deliver care. This care improves the quality of life for patients with IBS and is an effective intervention that is readily available. During pandemic times, the forum of online care also provides a safe way to deliver therapy services without the burden of the patient needing to commute to clinic and potentially be exposed to infectious disease. Given the relationship between IBS and psychiatric diagnoses noted by Creed and colleagues, it seems important to extend the availability of therapeutic interventions to as many patients with IBS as possible.
Commentary: Treatments for IBS, August 2022
The study by El-Sahy and colleagues highlights the novel role of fecal microbiota transplant (FMT) in the treatment of irritable bowel syndrome (IBS). The safety and efficacy of this treatment was durable and provided sustained symptom relief for 3 years after FMT in this study. Those treated with donor feces had significantly lower IBS Severity Scoring System scores. Notably, patients with diarrhea-predominant IBS and those with mixed IBS had significantly higher response rates than did those with constipation-predominant IBS at 2 years post-FMT, but response rates coalesced at year 3. Those who lost clinical response at year 3 were responsive to retransplantation. This supports the idea of developing a protocol for FMT for the treatment of patients with IBS.
The study by Huang and colleagues investigates the long-term effects and potential mechanisms of action of transcutaneous electrical acustimulation (TEA) in patients with IBS with constipation (IBS-C) experiencing colonic transit issues and visceral hypersensitivity. Patients with IBS-C receiving TEA had increased frequency of spontaneous bowel movements and significant improvements in analog pain score compared with the placebo group. This supports the benefit of TEA for improving constipation and the concomitant symptoms by accelerating colonic transit and reducing rectal sensation. It can be inferred that the improvement of these symptoms will lead to enhanced quality of life in patients with IBS-C.
The study by Melchior and colleagues1 emphasizes the effect that IBS can have on a patient's life. Patients with IBS report reduced disease-specific quality of life. The cumulative impact of the demographic factors and the severity of psychological symptoms, somatic symptoms, and gastrointestinal symptoms are associated with decreased quality of life. The severity of this impact is determined by the combination of these factors and the level of severity at which they occur. This decrease in quality of life can lead to increased anxiety related to gastrointestinal function. It is important for providers to acknowledge the effect that gastrointestinal function has on the patient's life in a broader sense. The appreciation and understanding of the patient experience enhances the therapeutic relationship and shared decision-making between the patient and the healthcare provider.
Additional References
- Melchior C, Colomier E, Trindade IA, et al. Irritable bowel syndrome: Factors of importance for disease-specific quality of life. United European Gastroenterol J. 2022 Jul 13. Doi: 10.1002/ueg2.12277
The study by El-Sahy and colleagues highlights the novel role of fecal microbiota transplant (FMT) in the treatment of irritable bowel syndrome (IBS). The safety and efficacy of this treatment was durable and provided sustained symptom relief for 3 years after FMT in this study. Those treated with donor feces had significantly lower IBS Severity Scoring System scores. Notably, patients with diarrhea-predominant IBS and those with mixed IBS had significantly higher response rates than did those with constipation-predominant IBS at 2 years post-FMT, but response rates coalesced at year 3. Those who lost clinical response at year 3 were responsive to retransplantation. This supports the idea of developing a protocol for FMT for the treatment of patients with IBS.
The study by Huang and colleagues investigates the long-term effects and potential mechanisms of action of transcutaneous electrical acustimulation (TEA) in patients with IBS with constipation (IBS-C) experiencing colonic transit issues and visceral hypersensitivity. Patients with IBS-C receiving TEA had increased frequency of spontaneous bowel movements and significant improvements in analog pain score compared with the placebo group. This supports the benefit of TEA for improving constipation and the concomitant symptoms by accelerating colonic transit and reducing rectal sensation. It can be inferred that the improvement of these symptoms will lead to enhanced quality of life in patients with IBS-C.
The study by Melchior and colleagues1 emphasizes the effect that IBS can have on a patient's life. Patients with IBS report reduced disease-specific quality of life. The cumulative impact of the demographic factors and the severity of psychological symptoms, somatic symptoms, and gastrointestinal symptoms are associated with decreased quality of life. The severity of this impact is determined by the combination of these factors and the level of severity at which they occur. This decrease in quality of life can lead to increased anxiety related to gastrointestinal function. It is important for providers to acknowledge the effect that gastrointestinal function has on the patient's life in a broader sense. The appreciation and understanding of the patient experience enhances the therapeutic relationship and shared decision-making between the patient and the healthcare provider.
Additional References
- Melchior C, Colomier E, Trindade IA, et al. Irritable bowel syndrome: Factors of importance for disease-specific quality of life. United European Gastroenterol J. 2022 Jul 13. Doi: 10.1002/ueg2.12277
The study by El-Sahy and colleagues highlights the novel role of fecal microbiota transplant (FMT) in the treatment of irritable bowel syndrome (IBS). The safety and efficacy of this treatment was durable and provided sustained symptom relief for 3 years after FMT in this study. Those treated with donor feces had significantly lower IBS Severity Scoring System scores. Notably, patients with diarrhea-predominant IBS and those with mixed IBS had significantly higher response rates than did those with constipation-predominant IBS at 2 years post-FMT, but response rates coalesced at year 3. Those who lost clinical response at year 3 were responsive to retransplantation. This supports the idea of developing a protocol for FMT for the treatment of patients with IBS.
The study by Huang and colleagues investigates the long-term effects and potential mechanisms of action of transcutaneous electrical acustimulation (TEA) in patients with IBS with constipation (IBS-C) experiencing colonic transit issues and visceral hypersensitivity. Patients with IBS-C receiving TEA had increased frequency of spontaneous bowel movements and significant improvements in analog pain score compared with the placebo group. This supports the benefit of TEA for improving constipation and the concomitant symptoms by accelerating colonic transit and reducing rectal sensation. It can be inferred that the improvement of these symptoms will lead to enhanced quality of life in patients with IBS-C.
The study by Melchior and colleagues1 emphasizes the effect that IBS can have on a patient's life. Patients with IBS report reduced disease-specific quality of life. The cumulative impact of the demographic factors and the severity of psychological symptoms, somatic symptoms, and gastrointestinal symptoms are associated with decreased quality of life. The severity of this impact is determined by the combination of these factors and the level of severity at which they occur. This decrease in quality of life can lead to increased anxiety related to gastrointestinal function. It is important for providers to acknowledge the effect that gastrointestinal function has on the patient's life in a broader sense. The appreciation and understanding of the patient experience enhances the therapeutic relationship and shared decision-making between the patient and the healthcare provider.
Additional References
- Melchior C, Colomier E, Trindade IA, et al. Irritable bowel syndrome: Factors of importance for disease-specific quality of life. United European Gastroenterol J. 2022 Jul 13. Doi: 10.1002/ueg2.12277
Commentary: Caring for Patients With IBD, July 2022
The importance of cancer screening and prevention in patients with inflammatory bowel disease (IBD) is highlighted by the study of Wu and colleagues. Patients who are taking immunosuppressive therapy should be screened at closer intervals than persons without IBD. Patients should complete all applicable vaccinations, including vaccination against human papillomavirus (HPV) to prevent the development of cervical cancer. Patients should be screened for dysplasia and colorectal cancer at an individualized interval determined by disease extent and duration. The findings of this study support the need for a comprehensive review of a patient's access to preventive services, dermatology services, gynecology services, and vaccines, and regular follow-up to continually review the appropriateness of therapy, based on health changes in the interval.
The study by D'Amico and colleagues underscores the importance of using biologic therapies early in the postoperative course to prevent endoscopic recurrence. Patients who require surgery should initiate biologic therapy as soon as they have completed postoperative healing. This will help prevent a recurrence of their Crohn's disease and limit the need for subsequent surgery in the future. Proactive monitoring for postoperative recurrence and prompt management of any inflammation identified is vital in improving long-term outcomes.
Meanwhile, Rosiou and colleagues highlight the importance of communication with the entire care team regarding the management of IBD flares. Proactive patient education about notifying the primary gastroenterology provider if they experience flare symptoms can help prevent inappropriate or excess steroid exposure. Steroid-sparing strategies for the induction and maintenance of IBD remission are pivotal in preventing side effects and long-term complications of steroid exposure. Steroids should be used as a short-term therapy while bridging to a safe and appropriate maintenance regimen.
The importance of cancer screening and prevention in patients with inflammatory bowel disease (IBD) is highlighted by the study of Wu and colleagues. Patients who are taking immunosuppressive therapy should be screened at closer intervals than persons without IBD. Patients should complete all applicable vaccinations, including vaccination against human papillomavirus (HPV) to prevent the development of cervical cancer. Patients should be screened for dysplasia and colorectal cancer at an individualized interval determined by disease extent and duration. The findings of this study support the need for a comprehensive review of a patient's access to preventive services, dermatology services, gynecology services, and vaccines, and regular follow-up to continually review the appropriateness of therapy, based on health changes in the interval.
The study by D'Amico and colleagues underscores the importance of using biologic therapies early in the postoperative course to prevent endoscopic recurrence. Patients who require surgery should initiate biologic therapy as soon as they have completed postoperative healing. This will help prevent a recurrence of their Crohn's disease and limit the need for subsequent surgery in the future. Proactive monitoring for postoperative recurrence and prompt management of any inflammation identified is vital in improving long-term outcomes.
Meanwhile, Rosiou and colleagues highlight the importance of communication with the entire care team regarding the management of IBD flares. Proactive patient education about notifying the primary gastroenterology provider if they experience flare symptoms can help prevent inappropriate or excess steroid exposure. Steroid-sparing strategies for the induction and maintenance of IBD remission are pivotal in preventing side effects and long-term complications of steroid exposure. Steroids should be used as a short-term therapy while bridging to a safe and appropriate maintenance regimen.
The importance of cancer screening and prevention in patients with inflammatory bowel disease (IBD) is highlighted by the study of Wu and colleagues. Patients who are taking immunosuppressive therapy should be screened at closer intervals than persons without IBD. Patients should complete all applicable vaccinations, including vaccination against human papillomavirus (HPV) to prevent the development of cervical cancer. Patients should be screened for dysplasia and colorectal cancer at an individualized interval determined by disease extent and duration. The findings of this study support the need for a comprehensive review of a patient's access to preventive services, dermatology services, gynecology services, and vaccines, and regular follow-up to continually review the appropriateness of therapy, based on health changes in the interval.
The study by D'Amico and colleagues underscores the importance of using biologic therapies early in the postoperative course to prevent endoscopic recurrence. Patients who require surgery should initiate biologic therapy as soon as they have completed postoperative healing. This will help prevent a recurrence of their Crohn's disease and limit the need for subsequent surgery in the future. Proactive monitoring for postoperative recurrence and prompt management of any inflammation identified is vital in improving long-term outcomes.
Meanwhile, Rosiou and colleagues highlight the importance of communication with the entire care team regarding the management of IBD flares. Proactive patient education about notifying the primary gastroenterology provider if they experience flare symptoms can help prevent inappropriate or excess steroid exposure. Steroid-sparing strategies for the induction and maintenance of IBD remission are pivotal in preventing side effects and long-term complications of steroid exposure. Steroids should be used as a short-term therapy while bridging to a safe and appropriate maintenance regimen.